ADAM KAUL: Open Payments
NPI 1689653107 · MIDLOTHIAN, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,247 in 52 payments from 9 companies in 2025. Trend: 2023 $6,803 · 2024 $876 · 2025 $1,247
Food & beverage: $1,247
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 20 | $515 |
| E.R. Squibb & Sons, L.L.C. | 9 | $262 |
| Vanda Pharmaceuticals Inc. | 9 | $158 |
| Otsuka America Pharmaceutical, Inc. | 3 | $75 |
| Teva Pharmaceuticals USA, Inc. | 3 | $69 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $56 |
| Janssen Pharmaceuticals, Inc | 2 | $47 |
| ABBVIE INC. | 2 | $43 |
| Lundbeck LLC | 1 | $22 |
Products named: INGREZZA, COBENFY, FANAPT, CAPLYTA, HETLIOZ, REXULTI, INVEGA SUSTENNA, ABILIFY MAINTENA.
Industry payments across VA — which companies pay providers there.
